Scinai Immunotherapeutics Ltd.
SCNI Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 30, 2026
$0.47
KIRA · Stoqly’s AI analyst, in plain words
- Scinai Immunotherapeutics Ltd. had only $1.3M of revenue in fiscal 2025: it is still developing what it sells. It spent $2.4M on research and development, 27% of its operating costs.
- Its operating margin was −575.3%, up 737.5 pts: of every 100 in sales, about −575 is left after running the business.
- Scinai Immunotherapeutics Ltd. lost $8.3M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$6.1M in fiscal 2025, −461.9% of revenue. At that burn of $6.1M a year, its $1.7M of cash and short-term investments would last about 0.3 years.
Market cap
—
P/E
—
Revenue
$1.3M
Net income
−$8.3M
Free cash flow
−$6.1M
Operating margin
−575.3%
Scinai Immunotherapeutics Ltd. in 30 seconds · fiscal 2025
Are shareholders being diluted?
+189.6%
A lot. The share count rose 189.6% last year, so each share owns noticeably less.
Does it make a profit?
$2.4M R&D
Not yet: it has no meaningful sales. It spent $2.4M on research and development, 27% of its operating costs.
How long would its cash last?
0.3 yrs
Not long. It burns $6.1M a year and holds $1.7M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
2 / 8
It passes 2 of 8 health tests, but most of them need sales, so the score says little before revenue starts.
What Scinai Immunotherapeutics Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 1, 2026
- Legal name
- Scinai Immunotherapeutics Ltd.
- CIK
- 0001611747
Scinai Immunotherapeutics Ltd. · SCNI · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $0.7M | $1.3M |
| Revenue growth | — | — | — | — | 99.2% |
| Gross margin | — | — | — | −88.1% | −202.3% |
| Operating margin | — | — | — | −1,312.8% | −575.3% |
| Net income | −$8.2M | −$5.8M | −$6.5M | $4.8M | −$8.3M |
| Net margin | — | — | — | 728.9% | −633.6% |
| Diluted EPS | −$0.02 | $0.01 | $0.00 | — | — |
| Cash | |||||
| Cash from operations | −$7.4M | −$7.3M | −$9.4M | −$6.3M | −$6.0M |
| Capital expenditure | $0.1M | $0.8M | $0.6M | $0.0M | $0.0M |
| Free cash flow | −$7.6M | −$8.1M | −$10.0M | −$6.3M | −$6.1M |
| FCF margin | — | — | — | −964.6% | −461.9% |
| Share count change | — | 33.6% | 107.2% | 106.4% | 189.6% |
| Debt and strength | |||||
| Cash and short-term investments | $17.4M | $14.1M | $4.9M | $2.0M | $1.7M |
| Debt incl. finance leases | $0.4M | $0.4M | — | — | — |
| Shareholders' equity | $1.0M | −$1.8M | −$4.6M | $10.0M | $8.1M |
| Current ratio | 7.3x | 6.1x | 3.1x | 1.3x | 1.3x |
| Interest coverage | −32.3x | −31.5x | −28.3x | — | — |
| Returns and quality | |||||
| Return on equity | −835.6% | — | — | 177.4% | −91.9% |
| Return on tangible equity | 835.6% | — | — | 48.1% | −102.5% |
| Piotroski F-score | — | 1 | — | — | 2 |
| Altman Z'' | −10.3 | −13.8 | −25.4 | −29.5 | −37.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Scinai Immunotherapeutics Ltd. · SCNI · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.47 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001611747). Latest version: stoqly.net/companies/scni. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.